- Datum01.09.2025
- Uhrzeit08:00 - 09:00 Uhr
- Veranstalter
XTB
Stefan Salomon
Moderator
uniQure N.V. Aktie
Verkaufen
Kaufen
uniQure N.V. Chart
uniQure N.V. Realtime-Kurs
| Handelsplatz | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| L&S | VK | |||||
| Tradegate | VK | |||||
| Stuttgart | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (Nasdaq)
0,43 %
Intraday
4,01 %
1 Woche
19,37 %
1 Monat
-7,53 %
Seit Jahresbeginn
162,54 %
1 Jahr
-16,60 %
3 Jahre
-58,22 %
5 Jahre
-36,63 %
10 Jahre
Passender Service zu uniQure N.V.
Webinar zu uniQure N.V.
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)4,450-19,180
- Jahrestief / Hoch ($)7,760-19,180
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von uniQure N.V.
Keine Dividenden verfügbar
Termine von uniQure N.V.
- Okt29uniQure N.V.Q3 2025 Earnings Release
- Mär2uniQure N.V.Q4 2025 Earnings Release
- Mai12uniQure N.V.Q1 2026 Earnings Release
Beschreibung
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
